213 related articles for article (PubMed ID: 33865567)
1. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract][Full Text] [Related]
2. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium.
Whitaker LH; Murray AA; Matthews R; Shaw G; Williams AR; Saunders PT; Critchley HO
Hum Reprod; 2017 Mar; 32(3):531-543. PubMed ID: 28130434
[TBL] [Abstract][Full Text] [Related]
3. Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
Levy G; Elkas J; Armstrong AY; Nieman LK
J Reprod Med; 2016; 61(3-4):159-62. PubMed ID: 27172639
[TBL] [Abstract][Full Text] [Related]
4. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
7. Absence of predictable long-term molecular effect of ulipristal acetate (UPA) on the endometrium.
Kolanska K; Varinot J; Canlorbe G; Bergeron C; Mekinian A; Capmas P; Koskas M; Daraï E; Aractingi S; Bendifallah S; Chabbert-Buffet N
Reprod Biomed Online; 2019 May; 38(5):825-834. PubMed ID: 30898512
[TBL] [Abstract][Full Text] [Related]
8. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Donnez J; Donnez O; Dolmans MM
Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
[TBL] [Abstract][Full Text] [Related]
9. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
10. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Williams AR; Bergeron C; Barlow DH; Ferenczy A
Int J Gynecol Pathol; 2012 Nov; 31(6):556-69. PubMed ID: 23018219
[TBL] [Abstract][Full Text] [Related]
11. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
12. Sonographic and hysteroscopic endometrial examination in women treated with ulipristal acetate: Exploratory findings at a tertiary referral center.
Gracia M; Nonell R; Ros C; Rius M; Quintas L; Martínez-Zamora MÁ; Carmona F
Eur J Obstet Gynecol Reprod Biol; 2019 Jan; 232():40-45. PubMed ID: 30468982
[TBL] [Abstract][Full Text] [Related]
13. The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids.
Bouchard P; Chabbert-Buffet N
Best Pract Res Clin Obstet Gynaecol; 2017 Apr; 40():105-110. PubMed ID: 28169130
[TBL] [Abstract][Full Text] [Related]
14. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
Osuga Y; Nakano Y; Yamauchi Y; Takanashi M
Fertil Steril; 2021 Jul; 116(1):189-197. PubMed ID: 33715871
[TBL] [Abstract][Full Text] [Related]
15. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review.
Donnez J; Courtoy GE; Donnez O; Dolmans MM
Reprod Biomed Online; 2018 Aug; 37(2):216-223. PubMed ID: 29706284
[TBL] [Abstract][Full Text] [Related]
16. Histomorphological changes in endometriosis in a patient treated with ulipristal: A case report.
Bateman J; Bougie O; Singh S; Islam S
Pathol Res Pract; 2017 Jan; 213(1):79-81. PubMed ID: 27914766
[TBL] [Abstract][Full Text] [Related]
17. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
18. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator.
Ioffe OB; Zaino RJ; Mutter GL
Mod Pathol; 2009 Mar; 22(3):450-9. PubMed ID: 19136935
[TBL] [Abstract][Full Text] [Related]
19. Endometrial Changes in Surgical Specimens of Perimenopausal Patients Treated With Ulipristal Acetate for Uterine Leiomyomas.
Nogales FF; Crespo-Lora V; Cruz-Viruel N; Chamorro-Santos C; Bergeron C
Int J Gynecol Pathol; 2018 Nov; 37(6):575-580. PubMed ID: 28914672
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]